Fig. 4From: Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery diseaseInteraction effect of baseline characteristics on the association of SGLT2 inhibitor use with restenosis risk in the propensity score-matched population. Error bars indicate 95% confidence intervals. SGLT2, sodium-glucose co-transporter 2Back to article page